Q: So, why did TTX raise now?

The Crucible of Capital: How TTX is Engineering the Asymmetric Future

To Our Tetratherix Shareholders

The fundamental validation of an industrial enterprise is found in the absolute, uncompromising alignment of its strategic execution with the raw, unmet demands of the global market. Today, Tetratherix stands at a definitive structural inflection point where our proprietary technology, clinical milestones, and commercial architecture have converged to establish an undeniable reality. This past week, we executed on an institutional placement because our operational trajectory will be intensified by an immediate acceleration of scale to capture the extraordinary value unfolding directly ahead of us. Although this capital injection is well ahead of schedule, it is not an auxiliary course correction, it is not a flippant response to a share price nor is it a standard balance sheet buffer meant to satisfy conventional metrics of corporate comfort. It is pure, high-velocity growth capital explicitly engineered to accelerate our path to free cash flow by fast tracking our production capabilities and dominating the massive structural shifts occurring in the global life sciences landscape. We are operating from a position of absolute strength and profound operational clarity, executing a strategy that has moved definitively from the theoretical domain into a highly scalable, high-margin commercial reality.

Since our listing in June 2025, our strategic vision has been systematically realised across every key metric. The clinical milestones we have achieved, the proprietary biomaterial advancements we have begun to commercialise, and the deep institutional partnerships we have solidified have conclusively proven that our Tetramatrix platform is the premier architectural foundation for the next generation of localised medicine. This realisation of our strategy has triggered an intense and highly concentrated demand for our equity from sophisticated global investors who recognise that the future of advanced medical platforms is being actively built by a hyper focused Australian group of medtech leaders. For months, the TTX thematic has been built on our capital structure via an exceptionally tight register. Our existing shareholders possess an acute, sophisticated understanding of the systemic value we are unlocking, creating a structural reality where transactional liquidity was rare because no one wants to sell their TTX position. This capital raise was investor-led, born out of intense, persistent incoming demand from institutions who made it abundantly clear that they desired a meaningful, scalable entry point into TTX stock to participate in the massive valuation creation curve we are driving forward.

By executing this capital layout now, we are solving the liquidity constraint for foundational institutions while simultaneously providing our loyal retail base with an equitable, parallel mechanism via the two million dollar Share Purchase Plan to maintain and expand their ownership stakes. We have listened closely to the market, and this capital structure optimisation represents the perfect synthesis of institutional demand and corporate stewardship. More importantly, this capital provides us with the definitive resources required to immediately bring our production readiness forward to meet the immense opportunity that is currently materialising on the horizon. The global explosion of interest and clinical reliance on GLP-1 agonists, peptides, and advanced intranasal delivery mechanisms represents one of the largest transformations in modern medicine. Tetratherix is uniquely positioned to sit at the absolute epicentre of this revolution, as our specialised platform offers the necessary structural and delivery innovations required to maximise the therapeutic potential of these compounds at scale. The scale of the upcoming opportunity in GLP-1 and peptides is truly monumental, and this extra balance sheet strength will help in our efforts to capture this market share.

But most importantly, this capital placement ensures that our manufacturing facilities, regulatory pathways, and automated infrastructure are brought into immediate operational alignment with the evolving highest volume demands of our global partners. We are building the hard infrastructure required to sustain multi-billion-dollar therapeutic pipelines, and we are doing it with an urgency that reflects our absolute confidence in our technological dominance. Central to this near-term industrial expansion is the commercialisation of our upcoming bone regeneration product launches. These imminent rollouts represent our first scaled revenues in the highly regulated medtech market, serving as the commercial vanguard for our broader proprietary polymer matrix. The rigorous regulatory approvals we are securing for these bone regeneration assets validate the safety, efficacy, and reproducibility of our manufacturing process under the strictest global standards. By pulling forward our future production readiness, we are directly accelerating the commercial manufacturing lines for these opportunities ensuring we can be ahead the clinical demand from both consumer health & surgical distribution networks. These products establish a highly predictable revenue foundation that de-risks our financial trajectory and demonstrates our capacity to transition complex biomaterial science into scaled commercial reality.

By compressing our production readiness timelines for both our osseous platforms and our pharmaceutical delivery systems, we are effectively pulled forward into our commercial phase, shifting our financial profile rapidly toward consistent, high-margin revenue generation. Capital of this raise is being directly funnelled into high-ROI infrastructure and immediate commercial deployment assets. The mathematical reality of this acceleration is that it fundamentally changes our long-term funding requirements.

The new TTX HQ being built in Sydney. Advanced manufacturing for global export.

The strength of our balance sheet now matches the strength of our intellectual property and clinical data, reducing execution risk and allowing our executive team to focus entirely on pure market capture. We see a clear, uncompromised path to generating free cash flow, driven by the realisation that our platform is fundamentally superior and globally necessary. The market is beginning to realise that what we have built at Tetratherix cannot be easily replicated or ignored; it is a foundational technological shift that will govern the delivery and efficacy of advanced therapeutics for the next decade and beyond. Our conviction is shared by the premier capital allocators who have initiated this raise, and it is reinforced daily by the operational breakthroughs achieved across our research and manufacturing sectors.

We are locking in our capital structure at the exact moment our operational engine goes into hyperdrive. We are entering this next phase with an aggressive focus on execution, leveraging our fortified balance sheet to secure market share, expand our partnership ecosystems, and drive unrelenting value via clinical outcomes for every individual human who needs them.

We must also recognise the profound role that our internal culture of relentless execution has played in bringing us to this moment. The engineering breakthroughs, the regulatory customisation, and the complex logistical frameworks that underpin our daily operations are executed by a team that operates with an intensity that is entirely unique to Tetratherix. This capital gives that team the ultimate toolset to maximise their output. We are now operating with a level of urgency that matches the immense responsibility we have to both our patients and our shareholders. The life sciences sector rewards those who possess both the technological superiority and the financial fortitude to execute at a systemic scale. With up to $17m in new capital, backed by an investor-led cohort of the highest calibre, Tetratherix is now fully armed to realise the absolute fullness of its global destiny.

As we look across the horizon, the trajectory is clear and the momentum is entirely on our side. We have listened to our investors, we have validated our technology, we have solidified our market positioning, and we have capitalised our business to ensure total execution. This is a moment of profound celebration for what we have built, but more importantly, it is a moment of intense focus for what we are about to unleash. The capital register has been optimised, the production timelines have been pulled forward, and the path to free cash flow is wide open. We will continue to execute with the same fierce, unyielding dedication that has brought us to this premier position, and we look forward to sharing the immense rewards of this journey with all of you. Thank you for your support and belief in our mission to change the lives of millions of humans, change the way things are done in our industry and to change the world.

Cheers,

Will